Hub : Traits :

Schizophrenia (2018)

482 significantly associated models · 131 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	35925590	37340877	1	1	2.1e-08	6.5e-08	1.0e+00	100	MAP7D1
2	1	242590540	244359621	3	3	3.1e-10	1.3e-08	7.9e-01	100	AKT3 CEP170 SDCCAG8
3	2	197134790	199079806	4	2	6.7e-11	4.0e-09	3.5e-01	98	ANKRD44 HSPD1
4	2	200086752	201571143	4	1	2.4e-12	2.1e-10	7.4e-02	92	C2orf47
5	2	224636490	226142508	1	1	5.5e-09	1.3e-06	4.4e-01	98	CUL3
6	3	1442951	3792945	1	1	2.3e-08	4.9e-10	1.2e-04	62	CNTN4
7	3	36235084	37614424	1	1	2.7e-07	7.6e-10	4.5e-04	68	AC011816.1
8	3	51655856	53560321	8	1	1.1e-08	3.7e-08	2.0e-01	95	ITIH4-AS1
9	3	63121945	64546545	1	1	2.8e-09	4.2e-09	1.0e+00	100	THOC7
10	3	135273949	137261517	4	1	2.5e-09	3.4e-09	1.0e+00	100	PCCB
11	4	169845720	171339965	1	1	1.9e-07	6.8e-08	1.2e-03	64	CLCN3
12	5	59474215	60936935	1	1	5.5e-09	2.2e-10	6.1e-03	81	ERCC8
13	5	100875868	102327463	1	1	2.0e-07	6.3e-07	7.0e-01	99	SLCO4C1
14	5	136972187	138380480	1	1	5.1e-10	2.1e-08	6.2e-03	76	FAM53C
15	5	139329962	140784895	5	1	1.5e-08	3.4e-07	4.0e-01	97	IK
16	6	24300846	24891985	1	1	2.9e-11	4.0e-05	6.5e-01	99	KIAA0319
17	6	25266147	26689223	2	2	1.1e-11	2.8e-21	8.2e-07	73	TRIM38 U91328.21
18	6	63737627	64273105	1	1	7.1e-09	1.8e-06	1.8e-01	92	LGSN
19	7	109603832	111895681	1	1	1.4e-08	2.0e-10	1.1e-03	74	IMMP2L
20	8	142839492	145286483	2	2	5.6e-08	4.7e-09	4.1e-05	51	BAI1 FAM83H
21	10	103313599	106042502	13	1	9.1e-17	2.7e-15	8.0e-01	100	AS3MT
22	11	45945837	47902883	6	1	2.6e-08	1.4e-09	1.0e+00	100	ATG13
23	11	63316786	64707978	1	1	5.6e-09	3.1e-06	8.6e-02	86	PPP1R14B
24	12	1204676	2805632	2	2	4.9e-10	1.3e-13	8.2e-05	72	CACNA2D4 DCP1B
25	12	110175537	111634281	2	1	5.2e-08	5.4e-09	2.6e-02	85	VPS29
26	12	122713991	124545118	9	1	1.8e-09	2.0e-09	2.4e-02	86	C12orf65
27	14	70676661	72273020	1	1	4.4e-09	2.9e-08	8.1e-01	100	PCNX
28	14	103161201	105211221	11	1	4.3e-11	5.8e-10	3.3e-02	88	PPP1R13B
29	15	78135979	79537269	2	1	3.6e-12	2.2e-12	1.0e+00	100	CHRNA5
30	15	84151637	86040394	10	1	1.6e-10	9.2e-10	5.5e-01	99	AC103965.1
31	15	90718541	92135418	3	1	1.0e-13	4.6e-12	3.8e-03	82	FES
32	16	28845251	30823047	3	1	5.9e-08	2.6e-07	9.0e-01	100	MAPK3
33	17	12198253	13613997	1	1	2.8e-07	3.9e-06	4.8e-01	98	ELAC2
34	17	17017584	18325085	4	1	2.6e-08	7.9e-08	1.0e+00	100	C17orf39
35	20	36681910	38094711	1	2	1.3e-08	5.4e-12	6.3e-04	75	ACTR5
36	22	39192995	40571499	1	1	1.1e-08	1.6e-09	4.4e-03	78	MGAT3
37	22	41641984	43232818	10	1	5.2e-09	7.8e-09	1.3e-02	82	NAGA
38	22	50070991	50559247	1	1	7.0e-08	1.1e-06	6.8e-01	99	CRELD2

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Schizophrenia (2014)	15.97	42	32	71.1	1.00	1.8e-43	AC011816.1 AC103965.1 ACTR5 AKT3 ANKRD44 AS3MT ATG13 BAI1 C12orf65 C17orf39 C2orf47 CACNA2D4 CEP170 CHRNA5 CLCN3 CNTN4 CRELD2 CUL3 DCP1B ELAC2 ERCC8 FAM53C FAM83H FES HSPD1 IK IMMP2L ITIH4-AS1 KIAA0319 LGSN MAP7D1 MAPK3 MGAT3 NAGA PCCB PCNX PPP1R13B PPP1R14B SDCCAG8 SLCO4C1 THOC7 VPS29
Bipolar Disorder or Schizophrenia	14.93	42	30	66.7	0.99	2.5e-35	AC011816.1 AC103965.1 ACTR5 AKT3 ANKRD44 AS3MT ATG13 BAI1 C12orf65 C17orf39 C2orf47 CACNA2D4 CEP170 CHRNA5 CLCN3 CNTN4 CRELD2 CUL3 DCP1B ELAC2 ERCC8 FAM53C FES HSPD1 IK IMMP2L ITIH4-AS1 KIAA0319 LGSN MAP7D1 MAPK3 MGAT3 NAGA PCCB PCNX PPP1R13B PPP1R14B SDCCAG8 SLCO4C1 THOC7 TRIM38 U91328.21
Pack years adult smoking proportion	4.77	2	1	2.2	0.00	1.0e+00	CHRNA5 PPP1R13B
Bipolar Disorder (2011)	4.58	2	0	0.0	0.00	1.0e+00	CACNA2D4 ITIH4-AS1
Pack years of smoking	4.33	2	1	2.2	0.00	1.0e+00	CHRNA5 PPP1R13B
Risk taking	4.16	4	2	4.4	0.68	3.2e-01	AKT3 CEP170 PCCB PPP1R13B
Bipolar Disorder (2018)	4.13	4	2	4.4	1.00	1.4e-03	AC103965.1 CACNA2D4 ITIH4-AS1 PPP1R14B
Schizophrenia vs Biploar Disorder	3.56	3	0	0.0	0.00	1.0e+00	ATG13 C17orf39 VPS29
Worry (Nagel 2018)	3.26	8	3	6.7	0.98	3.5e-05	AS3MT C2orf47 CACNA2D4 ITIH4-AS1 MAPK3 PCCB THOC7 TRIM38
Verbal and Numeric Reasoning (VNR)	3.11	5	2	4.4	-0.99	6.0e-04	IK ITIH4-AS1 MGAT3 NAGA U91328.21
Systolic Blood Pressure	2.98	9	6	13.3	0.05	8.9e-01	AS3MT C17orf39 C2orf47 FES IK PCNX PPP1R14B SDCCAG8 VPS29
Worrier / anxious feelings	2.93	5	3	6.7	0.98	4.5e-03	AS3MT C2orf47 CACNA2D4 ITIH4-AS1 PCCB
Impedance of leg (right)	2.91	9	6	13.3	0.22	5.6e-01	AC103965.1 AS3MT C17orf39 C2orf47 ERCC8 ITIH4-AS1 MAP7D1 MAPK3 PPP1R13B
Smoking Status	2.88	4	2	4.4	0.19	8.1e-01	AS3MT CUL3 ERCC8 PPP1R13B
Impedance of whole body	2.87	11	7	15.6	0.38	2.5e-01	AC103965.1 ANKRD44 AS3MT CACNA2D4 ERCC8 HSPD1 ITIH4-AS1 MAP7D1 MAPK3 PPP1R13B VPS29
Nervous feelings	2.82	4	4	8.9	0.99	6.2e-03	AS3MT ITIH4-AS1 MAPK3 PCCB
Impedance of leg (left)	2.80	9	6	13.3	0.22	5.7e-01	AC103965.1 AS3MT C17orf39 ERCC8 ITIH4-AS1 MAP7D1 MAPK3 MGAT3 PPP1R13B
Number of incorrect matches in round	2.74	2	1	2.2	0.00	1.0e+00	AS3MT MAPK3
Vascular/heart problems diagnosed by doctor	2.70	5	1	2.2	0.28	6.5e-01	AS3MT FES PCNX PPP1R13B PPP1R14B
Diastolic blood pressure, automated reading	2.68	6	4	8.9	-0.41	4.1e-01	C12orf65 CEP170 FES PPP1R13B SDCCAG8 U91328.21
Seen a psychiatrist for nerves, anxiety, tension or depression	2.67	2	0	0.0	0.00	1.0e+00	ACTR5 TRIM38
Intelligence (Savage-Jansen 2018)	2.66	6	2	4.4	-0.69	1.3e-01	C12orf65 IK IMMP2L ITIH4-AS1 MGAT3 PCCB
Medication for pain relief, constipation, heartburn	2.64	3	1	2.2	0.00	1.0e+00	PCNX SDCCAG8 U91328.21
Medication: Paracetamol	2.57	2	1	2.2	0.00	1.0e+00	SDCCAG8 U91328.21
Impedance of arm (left)	2.53	9	5	11.1	0.56	1.2e-01	AC103965.1 ANKRD44 AS3MT ERCC8 HSPD1 ITIH4-AS1 MAPK3 NAGA VPS29
Hypertension (Self-reported)	2.53	4	1	2.2	-0.96	4.2e-02	FES PCNX PPP1R14B SDCCAG8
High blood pressure	2.52	4	1	2.2	-0.95	4.9e-02	FES PCNX PPP1R14B SDCCAG8
Impedance of arm (right)	2.52	9	5	11.1	0.65	5.7e-02	AC103965.1 ANKRD44 AS3MT ERCC8 FAM53C HSPD1 ITIH4-AS1 MAPK3 VPS29
Ever smoked	2.52	1	0	0.0	0.00	1.0e+00	AS3MT
Hip circumference	2.50	9	4	8.9	-0.89	1.2e-03	AC103965.1 AS3MT BAI1 ERCC8 FAM83H ITIH4-AS1 MAPK3 TRIM38 VPS29
BMI	2.49	10	6	13.3	-0.50	1.4e-01	AKT3 AS3MT ATG13 BAI1 C2orf47 ITIH4-AS1 LGSN MAPK3 PPP1R13B VPS29
Headache pain in last month	2.48	3	3	6.7	0.00	1.0e+00	CEP170 SDCCAG8 U91328.21
Major Depression (MDD)	2.47	1	0	0.0	0.00	1.0e+00	MAP7D1
Illnesses of father: None of the above (group 1)	2.46	1	1	2.2	0.00	1.0e+00	FES
Fluid intelligence score	2.45	4	1	2.2	-0.60	4.0e-01	C12orf65 MGAT3 PCCB U91328.21
Medication: Blood pressure	2.45	2	1	2.2	0.00	1.0e+00	FES KIAA0319
Cardiovascular Disease	2.42	6	2	4.4	-0.38	4.5e-01	AS3MT FES PCCB PCNX PPP1R13B SDCCAG8
Weight	2.42	8	2	4.4	-0.75	3.2e-02	AC103965.1 AS3MT C2orf47 FAM83H MAP7D1 MAPK3 TRIM38 VPS29
Maternal smoking around birth	2.41	3	1	2.2	0.00	1.0e+00	AS3MT CHRNA5 PPP1R13B
Illnesses of father: High blood pressure	2.38	1	1	2.2	0.00	1.0e+00	FES
Seen doctor (GP) for nerves, anxiety, tension or depression	2.36	2	0	0.0	0.00	1.0e+00	ACTR5 U91328.21
Medication for cholesterol, blood pressure or diabetes	2.35	2	1	2.2	0.00	1.0e+00	FES PCNX
Leg fat-free mass (right)	2.35	10	3	6.7	-0.75	1.3e-02	AS3MT C2orf47 CEP170 ERCC8 FAM83H IK MAP7D1 MAPK3 MGAT3 VPS29
Leg fat-free mass (left)	2.34	11	4	8.9	-0.70	1.7e-02	AS3MT ATG13 C2orf47 CEP170 ERCC8 FAM83H MAP7D1 MAPK3 MGAT3 TRIM38 VPS29
Leg predicted mass (left)	2.34	11	4	8.9	-0.69	1.9e-02	AS3MT ATG13 C2orf47 CEP170 ERCC8 FAM83H MAP7D1 MAPK3 MGAT3 TRIM38 VPS29
Leg predicted mass (right)	2.33	10	3	6.7	-0.75	1.3e-02	AS3MT C2orf47 CEP170 ERCC8 FAM83H IK MAP7D1 MAPK3 MGAT3 VPS29
Waist Hip Ratio (WHR)	2.32	10	4	8.9	0.26	4.7e-01	AC103965.1 C12orf65 C17orf39 ERCC8 FAM53C ITIH4-AS1 MGAT3 PCCB PCNX SLCO4C1
Systolic blood pressure, automated reading	2.32	3	2	4.4	0.00	1.0e+00	AS3MT FES PPP1R14B
Basal metabolic rate	2.32	10	4	8.9	-0.74	1.5e-02	AS3MT C2orf47 CEP170 ERCC8 FAM83H IK MAP7D1 MAPK3 MGAT3 VPS29
Body mass index (BMI)	2.29	9	4	8.9	-0.68	4.3e-02	AS3MT ATG13 BAI1 C2orf47 ITIH4-AS1 MAPK3 PPP1R13B TRIM38 VPS29
Arm fat-free mass (left)	2.29	9	3	6.7	-0.70	3.6e-02	AS3MT ERCC8 FAM53C FAM83H HSPD1 MAP7D1 MAPK3 MGAT3 VPS29
Waist circumference	2.28	5	1	2.2	-0.69	1.9e-01	AS3MT BAI1 C2orf47 MAPK3 PPP1R13B
Frequency of tenseness / restlessness in last 2 weeks	2.28	1	1	2.2	0.00	1.0e+00	PCCB
Current tobacco smoking	2.27	4	0	0.0	0.27	7.3e-01	AS3MT CHRNA5 CUL3 PPP1R13B
High blood pressure (mother)	2.26	1	1	2.2	0.00	1.0e+00	FES
Arm fat mass (left)	2.26	9	2	4.4	-0.70	3.7e-02	AS3MT ATG13 BAI1 C2orf47 ITIH4-AS1 MAPK3 PPP1R13B TRIM38 VPS29
Arm predicted mass (left)	2.26	8	2	4.4	-0.71	4.9e-02	AS3MT ERCC8 FAM83H HSPD1 MAP7D1 MAPK3 MGAT3 VPS29
Mouth/teeth dental problems: Dentures	2.24	2	0	0.0	0.00	1.0e+00	CHRNA5 TRIM38
Arm fat-free mass (right)	2.24	9	4	8.9	-0.73	2.7e-02	AS3MT ERCC8 FAM53C FAM83H HSPD1 MAP7D1 MAPK3 MGAT3 VPS29
Arm predicted mass (right)	2.23	8	3	6.7	-0.85	7.0e-03	AS3MT ERCC8 FAM53C FAM83H HSPD1 MAPK3 MGAT3 VPS29
Whole body water mass	2.23	11	5	11.1	-0.73	1.1e-02	AS3MT C2orf47 CEP170 ERCC8 FAM53C FAM83H IK MAP7D1 MAPK3 MGAT3 VPS29
Past tobacco smoking	2.22	1	1	2.2	0.00	1.0e+00	AS3MT
Whole body fat-free mass	2.22	11	4	8.9	-0.73	1.1e-02	AS3MT C2orf47 CEP170 ERCC8 FAM53C FAM83H IK MAP7D1 MAPK3 MGAT3 VPS29
Medication: Ramipril	2.20	1	0	0.0	0.00	1.0e+00	FES
Chronic bronchitis/emphysema (father)	2.16	1	1	2.2	0.00	1.0e+00	CHRNA5
Arm fat mass (right)	2.16	8	1	2.2	-0.67	6.9e-02	AS3MT ATG13 BAI1 C2orf47 MAPK3 PPP1R13B TRIM38 VPS29
Tense / 'highly strung'	2.15	3	0	0.0	0.00	1.0e+00	CACNA2D4 MAPK3 PCCB
Leg fat mass (left)	2.15	8	3	6.7	-0.80	1.8e-02	AC103965.1 AS3MT ATG13 C2orf47 ITIH4-AS1 MAPK3 TRIM38 VPS29
Medication: Paracetamol	2.14	1	0	0.0	0.00	1.0e+00	U91328.21
Lung cancer (father)	2.12	1	1	2.2	0.00	1.0e+00	CHRNA5
Whole body fat mass	2.11	6	3	6.7	-0.83	4.1e-02	AC103965.1 AS3MT C2orf47 FAM83H MAPK3 TRIM38
Mean time to correctly identify matches	2.10	2	1	2.2	0.00	1.0e+00	ATG13 IMMP2L
Smoking status: Current	2.09	3	0	0.0	0.00	1.0e+00	AS3MT CUL3 PPP1R13B
Trunk fat mass	2.08	6	3	6.7	-0.86	2.8e-02	AC103965.1 AS3MT C2orf47 FAM83H MAPK3 TRIM38
Ever depressed for a whole week	2.08	1	0	0.0	0.00	1.0e+00	AKT3
Leg fat mass (right)	2.06	6	3	6.7	-0.89	1.7e-02	AC103965.1 AS3MT ITIH4-AS1 MAPK3 TRIM38 VPS29
Trunk fat-free mass	2.05	9	5	11.1	-0.68	4.2e-02	AS3MT ERCC8 FAM53C FAM83H HSPD1 MAP7D1 MAPK3 MGAT3 VPS29
Frequency of tiredness / lethargy in last 2 weeks	2.05	1	0	0.0	0.00	1.0e+00	PPP1R13B
Trunk predicted mass	2.04	9	5	11.1	-0.69	4.2e-02	AS3MT ERCC8 FAM53C FAM83H HSPD1 MAP7D1 MAPK3 MGAT3 VPS29
Forced expiratory volume in 1-second (FEV1), predicted percentage	2.02	4	3	6.7	-0.28	7.2e-01	CHRNA5 MAPK3 TRIM38 U91328.21
Reaction Time	2.00	3	1	2.2	0.00	1.0e+00	ATG13 C2orf47 IMMP2L
Suffer from 'nerves'	2.00	1	0	0.0	0.00	1.0e+00	AS3MT
Forced expiratory volume in 1-second (FEV1)	1.99	6	5	11.1	-0.40	4.3e-01	AC103965.1 CEP170 CHRNA5 IK TRIM38 U91328.21
Neuroticism	1.96	3	2	4.4	0.00	1.0e+00	AS3MT CRELD2 PCCB
Multivitamins +/- minerals	1.96	1	0	0.0	0.00	1.0e+00	BAI1
Medication: Ibuprofen (e.g. Nurofen)	1.95	1	0	0.0	0.00	1.0e+00	U91328.21
Depression (Nagel 2018)	1.94	1	0	0.0	0.00	1.0e+00	PCCB
Forced expiratory volume in 1-second (FEV1), Best measure	1.93	6	4	8.9	-0.41	4.2e-01	AC103965.1 CEP170 CHRNA5 IK TRIM38 U91328.21
Allergy or Eczema	1.92	3	2	4.4	0.00	1.0e+00	ANKRD44 C17orf39 HSPD1
Comparative height size at age 10	1.92	10	5	11.1	0.09	8.1e-01	AC103965.1 CRELD2 FAM83H FES ITIH4-AS1 MAP7D1 MAPK3 PCCB SLCO4C1 U91328.21
Alcohol drinker status: Previous	1.92	1	0	0.0	0.00	1.0e+00	PPP1R13B
Frequency of unenthusiasm / disinterest in last 2 weeks	1.91	1	0	0.0	0.00	1.0e+00	PCCB
Birth weight of first child	1.91	2	1	2.2	0.00	1.0e+00	AS3MT FES
Heart disease (mother)	1.91	1	0	0.0	0.00	1.0e+00	MAP7D1
Neuroticism (Nagel 2018)	1.90	2	1	2.2	0.00	1.0e+00	AS3MT PCCB
Fed-up feelings	1.86	1	1	2.2	0.00	1.0e+00	PCCB
Reason for reducing amount of alcohol drunk: Health precaution	1.86	1	0	0.0	0.00	1.0e+00	ACTR5
Qualifications: College or University degree	1.85	4	2	4.4	-0.13	8.7e-01	C12orf65 CEP170 ERCC8 MGAT3
Hearing difficulty/problems with background noise	1.83	1	0	0.0	0.00	1.0e+00	PPP1R13B
Comparative body size at age 10	1.82	3	1	2.2	0.00	1.0e+00	ERCC8 MAPK3 U91328.21
Hearing aid user	1.82	1	0	0.0	0.00	1.0e+00	ERCC8
Illnesses of father: Heart disease	1.81	1	1	2.2	0.00	1.0e+00	FES
Hearing difficulty/problems: Yes	1.78	1	0	0.0	0.00	1.0e+00	AKT3
Medication: Amlodipine	1.78	1	1	2.2	0.00	1.0e+00	FES
Alcohol usually taken with meals	1.77	1	0	0.0	0.00	1.0e+00	ERCC8
Asthma	1.77	2	1	2.2	0.00	1.0e+00	TRIM38 U91328.21
Arm fat percentage (right)	1.75	6	1	2.2	-0.52	2.9e-01	ANKRD44 AS3MT ATG13 C2orf47 MAPK3 PPP1R13B
Arm fat percentage (left)	1.75	7	1	2.2	-0.50	2.5e-01	ANKRD44 AS3MT ATG13 C2orf47 MAPK3 PPP1R13B TRIM38
Trunk fat percentage	1.74	4	2	4.4	-0.50	5.0e-01	AC103965.1 ANKRD44 MAPK3 TRIM38
Worry too long after embarrassment	1.72	1	1	2.2	0.00	1.0e+00	PCCB
Asthma (self-reported)	1.71	2	1	2.2	0.00	1.0e+00	TRIM38 U91328.21
Neuroticism score	1.70	1	1	2.2	0.00	1.0e+00	PCCB
Overall health rating	1.69	1	0	0.0	0.00	1.0e+00	C17orf39
Medication: Blood pressure	1.69	1	1	2.2	0.00	1.0e+00	FES
Number of live births	1.67	1	0	0.0	0.00	1.0e+00	FAM83H
Body fat percentage	1.67	4	2	4.4	-0.60	4.0e-01	AC103965.1 ANKRD44 MAPK3 TRIM38
Heart attack	1.65	1	0	0.0	0.00	1.0e+00	FES
Guilty feelings	1.65	1	0	0.0	0.00	1.0e+00	KIAA0319
Frequency of depressed mood in last 2 weeks	1.64	1	0	0.0	0.00	1.0e+00	PCCB
Number of operations (self-reported)	1.64	1	0	0.0	0.00	1.0e+00	ERCC8
Heart attack/myocardial infarction (self-reported)	1.64	1	0	0.0	0.00	1.0e+00	FES
Qualifications: A levels/AS levels or equivalent	1.63	3	0	0.0	0.00	1.0e+00	C12orf65 ERCC8 MGAT3
Coronary Artery Disease (CAD)	1.62	2	0	0.0	0.00	1.0e+00	AS3MT C17orf39
Smoking status: Previous	1.61	1	0	0.0	0.00	1.0e+00	KIAA0319
Mineral and other dietary supplements	1.61	1	0	0.0	0.00	1.0e+00	BAI1
Number of treatments/medications taken	1.60	1	1	2.2	0.00	1.0e+00	FES
Mouth/teeth dental problems	1.60	1	0	0.0	0.00	1.0e+00	PPP1R13B
Depressed Affect (Nagel 2018)	1.59	2	0	0.0	0.00	1.0e+00	CEP170 PCCB
Relative age of first facial hair	1.59	2	1	2.2	0.00	1.0e+00	AKT3 CEP170
Hayfever, allergic rhinitis or eczema	1.59	2	2	4.4	0.00	1.0e+00	ANKRD44 HSPD1
Forced vital capacity (FVC)	1.58	7	1	2.2	-0.05	9.1e-01	AC103965.1 CEP170 CHRNA5 CUL3 IK TRIM38 U91328.21
Father's age at death	1.58	2	1	2.2	0.00	1.0e+00	CHRNA5 FES
Birth weight	1.58	2	1	2.2	0.00	1.0e+00	AS3MT FES
Medication: Bendroflumethiazide	1.58	1	0	0.0	0.00	1.0e+00	FES
Illnesses of mother	1.57	1	1	2.2	0.00	1.0e+00	FES
Qualifications: O levels/GCSEs or equivalent	1.57	1	0	0.0	0.00	1.0e+00	C12orf65
Medication: Aspirin	1.57	1	1	2.2	0.00	1.0e+00	FES
Neuroticism (2016)	1.56	1	0	0.0	0.00	1.0e+00	THOC7
Qualifications: None of the above	1.56	1	1	2.2	0.00	1.0e+00	ERCC8
Medication: Atenolol	1.54	1	1	2.2	0.00	1.0e+00	FES
Qualifications: nursing, teaching	1.54	1	0	0.0	0.00	1.0e+00	ERCC8
Chronic bronchitis/emphysema (mother)	1.53	1	1	2.2	0.00	1.0e+00	CHRNA5
Leg fat percentage (left)	1.53	3	1	2.2	0.00	1.0e+00	AC103965.1 MAPK3 TRIM38
Prostate Cancer	1.51	1	0	0.0	0.00	1.0e+00	FAM83H
Medication: Cholesterol lowering	1.51	1	1	2.2	0.00	1.0e+00	FES
Long-standing illness, disability or infirmity	1.49	1	0	0.0	0.00	1.0e+00	PPP1R13B
Age when periods started (menarche)	1.48	2	1	2.2	0.00	1.0e+00	AKT3 MAPK3
Pulse rate	1.48	2	0	0.0	0.00	1.0e+00	C17orf39 ITIH4-AS1
Pulse rate, automated reading	1.48	3	1	2.2	0.00	1.0e+00	C17orf39 ITIH4-AS1 VPS29
Financial difficulties in last 2 years	1.47	1	1	2.2	0.00	1.0e+00	PPP1R13B
Leg fat percentage (right)	1.47	3	1	2.2	0.00	1.0e+00	AC103965.1 MAPK3 TRIM38
Miserableness	1.46	1	0	0.0	0.00	1.0e+00	CEP170
Forced vital capacity (FVC), Best measure	1.45	6	2	4.4	0.29	5.8e-01	AC103965.1 CEP170 CUL3 IK TRIM38 U91328.21
Breast Cancer	1.44	1	1	2.2	0.00	1.0e+00	FES
Angina (self-reported)	1.39	1	1	2.2	0.00	1.0e+00	FES
Forced expiratory volume in 1-second (FEV1), predicted	1.39	1	1	2.2	0.00	1.0e+00	AC103965.1
Blood Red Count	1.38	9	4	8.9	0.48	1.9e-01	ANKRD44 AS3MT C12orf65 C17orf39 C2orf47 ITIH4-AS1 LGSN MAPK3 VPS29
Angina	1.38	1	1	2.2	0.00	1.0e+00	FES
Illness, injury, bereavement, stress in last 2 years	1.36	1	0	0.0	0.00	1.0e+00	PPP1R13B
Allergy	1.32	2	2	4.4	0.00	1.0e+00	ANKRD44 HSPD1
Medication: Aspirin	1.32	1	1	2.2	0.00	1.0e+00	FES
Sensitivity / hurt feelings	1.30	1	0	0.0	0.00	1.0e+00	PCCB
Height	1.29	18	12	26.7	-0.35	1.5e-01	AC103965.1 AS3MT C12orf65 C17orf39 CEP170 CRELD2 FAM83H FES IK ITIH4-AS1 MAP7D1 MAPK3 MGAT3 PCCB PPP1R13B SDCCAG8 SLCO4C1 THOC7
Medication: Simvastatin	1.27	1	0	0.0	0.00	1.0e+00	FES
Standing height	1.26	12	3	6.7	-0.31	3.3e-01	AC103965.1 AS3MT C17orf39 CEP170 FAM83H IK ITIH4-AS1 MAPK3 MGAT3 SDCCAG8 SLCO4C1 U91328.21
Pain experienced in last month	1.26	1	0	0.0	0.00	1.0e+00	CUL3
Hand grip strength (left)	1.25	3	0	0.0	0.00	1.0e+00	AS3MT MAPK3 NAGA
Heel bone mineral density (BMD) T-score, automated (right)	1.24	2	0	0.0	0.00	1.0e+00	ATG13 KIAA0319
Lung FEV1/FVC ratio	1.21	5	2	4.4	-0.51	3.8e-01	AC103965.1 C17orf39 CHRNA5 ITIH4-AS1 MAPK3
Crohns Disease (2012)	1.20	1	0	0.0	0.00	1.0e+00	CRELD2
Heel bone mineral density (BMD) T-score, automated (left)	1.20	1	0	0.0	0.00	1.0e+00	ATG13
Sitting height	1.20	9	4	8.9	-0.54	1.3e-01	AC103965.1 AKT3 C12orf65 C17orf39 FAM53C FAM83H IK MGAT3 THOC7
Wheeze or whistling in the chest in last year	1.19	1	0	0.0	0.00	1.0e+00	MAPK3
Leg pain on walking	1.18	1	0	0.0	0.00	1.0e+00	PCNX
High blood pressure (siblings)	1.17	1	0	0.0	0.00	1.0e+00	FES
Ever had prostate specific antigen (PSA) test	1.17	1	0	0.0	0.00	1.0e+00	U91328.21
Respiratory disease	1.16	1	0	0.0	0.00	1.0e+00	ANKRD44
Medication for cholesterol	1.16	1	0	0.0	0.00	1.0e+00	FES
Peak expiratory flow (PEF)	1.13	1	0	0.0	0.00	1.0e+00	U91328.21
Blood White Count	1.12	11	5	11.1	0.55	8.1e-02	AKT3 C17orf39 FES IK LGSN MAPK3 MGAT3 NAGA PCCB PPP1R13B THOC7
Alcohol intake versus 10 years previously	1.10	1	0	0.0	0.00	1.0e+00	MAPK3
High cholesterol (Self-reported)	1.09	1	0	0.0	0.00	1.0e+00	PCNX
Blood Platelet Count	1.08	11	6	13.3	-0.39	2.3e-01	AC011816.1 AC103965.1 ANKRD44 AS3MT C12orf65 CRELD2 HSPD1 ITIH4-AS1 KIAA0319 MAP7D1 PCCB
Illnesses of siblings	1.06	1	0	0.0	0.00	1.0e+00	FES
Heel T-Score	1.05	4	3	6.7	0.71	2.9e-01	ATG13 CRELD2 MAPK3 PPP1R13B
Lung FVC	1.04	4	1	2.2	-0.35	6.5e-01	C17orf39 CHRNA5 CUL3 IK
Alcohol intake frequency.	1.02	3	0	0.0	0.00	1.0e+00	BAI1 CHRNA5 MAPK3
Hand grip strength (right)	0.87	1	0	0.0	0.00	1.0e+00	NAGA
Blood Eosinophil Count	0.81	5	3	6.7	0.66	2.3e-01	AC103965.1 C17orf39 ITIH4-AS1 MAPK3 PPP1R13B
Tanning	0.30	3	0	0.0	0.00	1.0e+00	CRELD2 ERCC8 ITIH4-AS1
Hair Pigment	0.17	4	3	6.7	0.56	4.4e-01	FAM53C FES PCNX PPP1R13B

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Prostate	4	0.49	2.5
GTEx	Brain Cerebellum	2	0.10	2.4
GTEx	Breast Mammary Tissue	12	0.63	2.4
GTEx	Pancreas	6	0.38	2.4
GTEx	Brain Cortex	6	0.59	2.3
GTEx	Breast Mammary Tissue (Male)	6	0.52	2.3
GTEx	Cells EBV-transformed lymphocytes	8	0.58	2.3
GTEx	Colon Transverse	5	0.25	2.3
GTEx	Esophagus Mucosa	11	0.34	2.3
GTEx	Liver	4	0.57	2.3
GTEx	Ovary	3	0.34	2.3
GTEx	Small Intestine Terminal Ileum	1	0.22	2.3
GTEx	Testis	22	0.71	2.3
GTEx	Adipose Subcutaneous	14	0.41	2.2
GTEx	Adipose Visceral Omentum	5	0.25	2.2
GTEx	Artery Aorta	11	0.38	2.2
GTEx	Artery Coronary	2	0.17	2.2
GTEx	Artery Tibial	14	0.38	2.2
GTEx	Brain Caudate basal ganglia	3	0.33	2.2
GTEx	Brain Frontal Cortex BA9	2	0.22	2.2
GTEx	Brain Hippocampus	0	0.00	2.2
GTEx	Breast Mammary Tissue (Female)	6	0.38	2.2
GTEx	Cells Transformed fibroblasts	16	0.39	2.2
GTEx	Colon Sigmoid	6	0.42	2.2
GTEx	Esophagus Gastroesophageal Junction	7	0.50	2.2
GTEx	Esophagus Muscularis	15	0.48	2.2
GTEx	Heart Atrial Appendage	3	0.19	2.2
GTEx	Heart Left Ventricle	5	0.34	2.2
GTEx	Lung	7	0.25	2.2
GTEx	Pituitary	4	0.37	2.2
GTEx	Skin Not Sun Exposed Suprapubic	9	0.37	2.2
GTEx	Skin Sun Exposed Lower leg	9	0.25	2.2
GTEx	Spleen	5	0.36	2.2
GTEx	Thyroid	16	0.41	2.2
GTEx	Whole Blood	8	0.41	2.2
ROSMAP	Brain Pre-frontal Cortex	13	0.30	2.2
CommonMind	Brain Pre-frontal Cortex	15	0.28	2.2
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	8	0.51	2.2
The Cancer Genome Atlas	Esophageal Carcinoma	2	0.30	2.2
The Cancer Genome Atlas	Glioblastoma Multiforme	5	0.51	2.2
The Cancer Genome Atlas	Stomach Adenocarcinoma	4	0.25	2.2
GTEx	Adrenal Gland	5	0.35	2.1
GTEx	Brain Cerebellar Hemisphere	3	0.21	2.1
GTEx	Brain Hypothalamus	2	0.35	2.1
GTEx	Brain Nucleus accumbens basal ganglia	1	0.12	2.1
GTEx	Brain Putamen basal ganglia	1	0.16	2.1
GTEx	Muscle Skeletal	6	0.21	2.1
GTEx	Nerve Tibial	13	0.31	2.1
GTEx	Stomach	4	0.28	2.1
GTEx	Uterus	1	0.18	2.1
The Cancer Genome Atlas	Breast Invasive Carcinoma	8	0.19	2.1
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	2	0.19	2.1
The Cancer Genome Atlas	Colon Adenocarcinoma	6	0.31	2.1
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	9	0.23	2.1
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	9	0.46	2.1
The Cancer Genome Atlas	Brain Lower Grade Glioma	6	0.15	2.1
The Cancer Genome Atlas	Lung Adenocarcinoma	9	0.32	2.1
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	7	0.29	2.1
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	6	0.39	2.1
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	2	0.13	2.1
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	4	0.32	2.1
The Cancer Genome Atlas	Prostate Adenocarcinoma	9	0.20	2.1
The Cancer Genome Atlas	Soft Tissue Sarcoma	2	0.20	2.1
The Cancer Genome Atlas	Thyroid Carcinoma	20	0.40	2.1
GTEx	Vagina	2	0.32	2.0
METSIM	Adipose	8	0.18	2.0
NTR	Blood	6	0.25	2.0
YFS	Blood	12	0.26	2.0
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	4	0.15	2.0
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	3	0.28	2.0
The Cancer Genome Atlas	Rectum Adenocarcinoma	2	0.30	2.0
The Cancer Genome Atlas	Testicular Germ Cell Tumors	6	0.49	2.0
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.00	1.9
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.00	1.7